HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it has accepted the resignation of its Chief Financial Officer, Michael Kalb, effective June 29, 2016. Mr. Kalb is leaving to accept the position of CFO at another public company.

Mr. Kalb’s resignation is not the result of any dispute or disagreement with the Company including any matters relating to the Company’s accounting practices or financial reporting.

Mr. Sundaram, Taro’s CEO, stated, “On behalf of the Company, we want to thank Mike for his many contributions to the Company during his seven year tenure at Taro, including his leadership of Taro’s finance team and our listing on the New York Stock Exchange. We wish him continued success in his new position.”

The company has initiated an external search for a full time successor as CFO.

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website atwww.taro.com.